Certified by Founder Lodge
Epsilogen Ltd
United Kingdom - Hammersmith START UP
1 Disclosed Funding Rounds $16,370,899
0 Participating Investments
- Founded date
2016
- Operating Status
Active
- Last Funding Type
Seed
- Company Type
For Profit
- Website
- Contact
- Social Links
Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours includi
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| September, 10 ,2024 | Series B | $16,370,899 |
British Patient Capital
3B Future Health Fund I & II
Epidarex Capital
ALSA Ventures
IDRx
CAMP4 Therapeutics
Delfi Diagnostics
xilis
Manifold Bio
Further AI | $5,000,000 | (Apr 3, 2025)
SchoolAI | $25,000,000 | (Apr 3, 2025)
Vivere | $7,500,000 | (Apr 3, 2025)
TrialKit | $4,250,000 | (Apr 3, 2025)
TwinKnowledge | $3,700,000 | (Apr 3, 2025)
